Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar OttawaGuy (< 20) Submitted: 8/12/2013 11:09:30 PM : Outperform Start Price: $4.90 EXEL Score: +2.68

Too much to list, Prostate, Breast, Brain,,,,,,____ Cancer. Also bone scan resolution, and many tests in Phase 2 and 3.

Product has been approved for use by FDE for MTC and is avail in Europe under the Indiv Program.

Featured Broker Partners


Advertisement